Pharmacodynamic breakpoints for ciprofloxacin efficacy and resistance in critically ill patients treated with continuous venovenous hemodialysis: a prospective case series study.

Pharmacodynamic breakpoints for ciprofloxacin efficacy and resistance in critically ill patients treated with continuous venovenous hemodialysis: a prospective case series study. - Ciprofloxacin pharmacodynamics in ICU-patients on CVVHD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41806

Enrollment

Registered

2014-12-18

Start date

2015-02-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial infection Renal Insufficiency

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Admission to the ICU of the Zaandam Medical Center during the study period • Expected to be undergoing CVVHD for >24 h • Treatment with ciprofloxacin for any infection or suspected infection, as judged by the attending physician. • Age >= 18 years

Exclusion criteria

Exclusion criteria: • Cessation of renal replacement therapy before obtainment of a through sample • No CRRT delivered during >25 % of the interval between obtainment of peak and through plasma samples.

Design outcomes

Primary

Measure	Time frame
The primary endpoint in our study is the theoretical pharmacodynamic breakpoint for efficacy, calculated by means of the following formula: TP BPeff = AUC24-ss / 125 (where AUC24-ss is the estimated AUC at steady state during a 12 h dosing interval multiplied by 2)	—

Secondary

Measure	Time frame
The secondary endpoint in our study is the theoretical pharmacodynamic breakpoint for the emergence of resistance, calculated by means of the following formula: TP BPres = Cmax-ss / 10 (where Cmax-ss is the estimated plasma concentration 30 minutes after ending a ciprofloxacin infusion at steady state)	—

Countries

Netherlands

Outcome results